How Wells Fargo Currently Rates Sangamo Biosciences Inc (NASDAQ:SGMO)
New York: Sangamo Biosciences Inc (NASDAQ:SGMO) coverage has been initiated with a “Outperform” rating by equity research analysts at Wells Fargo. This was issued to clients and investors in analysts note on 4 December.
From a total of 4 analysts covering Sangamo Biosciences (NASDAQ:SGMO) stock, 6 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is $30 while the lowest target price is $14. The mean of all analyst targets is $19.25 with a 94.95% above today’s ($8.72) stock price. Sangamo Biosciences was the topic of 7 analyst reports since August 8, 2015 according to the firm StockzIntelligence Inc. Jefferies reinitiated shares on October 23 with “Buy” rating. Jefferies maintained shares with “Buy” rating and $12 target share price in a report from a September 2. Cowen & Co maintained SGMO stock in a recent report from September 4 with “Buy” rating. JP Morgan maintained the rating on August 8. JP Morgan has a “Overweight” rating and a $22 price target on shares. Finally, Wedbush maintained the stock with “Buy” rating in a report issued on a September 2.
The stock closed the day at $8.72 during the previous session. It is down 31.93% since May 1, 2015 and is downtrending. It has underperformed by 29.15% the S&P500.
Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $610.81 million. The Firm is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. It currently has negative earnings. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics.
According to Zacks Investment Research, “Sangamo BioSciences, Inc. is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. The Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins.” Get a free copy of the Zacks research report on Sangamo Biosciences, Inc. (SGMO).